Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807395 | 0.74 | MCL1 (0.47) | KMT2ATERTMCL1DAOALDH1A1 | |
| SCHEMBL29061991 | 0.72 | KMT2A (0.44) | KMT2ATERTMCL1DAOALDH1A1 | |
| SCHEMBL3295316 | 0.71 | TRPA1 (0.42) | KMT2AALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL2610138 | 0.71 | TRPA1 (0.42) | KMT2AALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL2610142 | 0.70 | UGT2B7 (0.43) | KMT2AMEN1ADRA2ATSHR | |
| SCHEMBL9565143 | 0.70 | KMT2A (0.52) | KMT2ATERTMCL1DAOALDH1A1 | |
| SCHEMBL9887744 | 0.69 | KMT2A (0.55) | KMT2ATERTMCL1DAOALDH1A1 | |
| SCHEMBL10978547 | 0.69 | CYP2A6 (0.45) | KMT2AALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL12260539 | 0.68 | KMT2A (0.53) | KMT2ATERTMCL1DAOALDH1A1 | |
| SCHEMBL13354733 | 0.67 | KMT2A (0.49) | KMT2ATERTMCL1DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| EP-3830087-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025587-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020025587-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-02-06 | — | — | WO | disclosed |
| EP-3604309-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3604309-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | NQO1, ALPI, LCT | KMT2A 2727/4885TERT 1383/4885MCL1 497/4885 |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, ALPI, LCT | KMT2A 2727/4885TERT 1383/4885MCL1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.